Shares of 10x Genomics (NASDAQ:TXG – Get Free Report) shot up 5.8% during mid-day trading on Thursday. The stock traded as high as $61.09 and last traded at $60.3820. 576,391 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 3,004,482 shares. The stock had previously closed at $57.07.
Wall Street Analysts Forecast Growth
TXG has been the topic of several research analyst reports. Wall Street Zen raised 10x Genomics from a “hold” rating to a “buy” rating in a research report on Saturday, November 14th. Barclays lowered their price target on shares of 10x Genomics from $110.00 to $70.00 and set an “overweight” rating on the stock in a report on Monday, November 9th. Piper Sandler upped their price objective on 10x Genomics from $47.00 to $80.00 and gave the company a “neutral” rating in a research note on Monday, September 28th. JPMorgan Chase & Co. reduced their target price on shares of 10x Genomics from $70.00 to $65.00 and set a “neutral” rating for the company in a research note on Monday, November 9th. Finally, Stephens lowered 10x Genomics from an “overweight” rating to an “equal weight” rating in a research note on Friday, October 23rd. Five research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, 10x Genomics presently has an average rating of “Hold” and an average price target of $68.40.
View Our Latest Analysis on TXG
10x Genomics Stock Performance
The stock has a 50-day moving average price of $72.86 and a two-hundred day moving average price of $43.45. The stock has a market capitalization of $6.80 billion, a P/E ratio of -99.42 and a beta of 2.03.
10x Genomics (NASDAQ:TXG – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.12. 10x Genomics had a negative return on equity of 8.19% and a negative net margin of 10.84%. The business had revenue of $150.67 million for the quarter, compared to analysts’ expectations of $147.96 million. During the same period in the previous year, the firm posted ($0.22) EPS. The business’s revenue was up 1.1% on a year-over-year basis. Equities analysts anticipate that 10x Genomics will post -0.67 earnings per share for the current fiscal year.
Insider Activity
In other 10x Genomics news, Director John Stuelpnagel sold 20,000 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total transaction of $1,235,000.00. Following the completion of the sale, the director directly owned 328,436 shares in the company, valued at approximately $20,280,923. The trade was a 5.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Benjamin Hindson sold 13,818 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $63.02, for a total value of $870,810.36. Following the completion of the transaction, the insider directly owned 488,182 shares in the company, valued at $30,765,229.64. The trade was a 2.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 190,333 shares of company stock worth $12,604,970. 8.84% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quantinno Capital Management LP lifted its holdings in shares of 10x Genomics by 16.0% during the 1st quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock valued at $114,892,000 after acquiring an additional 744,558 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of 10x Genomics by 8.1% in the third quarter. Goldman Sachs Group Inc. now owns 3,403,142 shares of the company’s stock valued at $307,508,000 after purchasing an additional 254,283 shares during the period. Dimensional Fund Advisors LP lifted its holdings in 10x Genomics by 34.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,042,950 shares of the company’s stock worth $43,357,000 after buying an additional 525,369 shares in the last quarter. First Trust Advisors LP boosted its holdings in 10x Genomics by 8.8% in the third quarter. First Trust Advisors LP now owns 451,226 shares of the company’s stock valued at $40,773,000 after purchasing an additional 36,332 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new stake in shares of 10x Genomics during the first quarter worth approximately $5,945,000. 84.68% of the stock is currently owned by institutional investors.
10x Genomics Company Profile
10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.
Featured Articles
- Five stocks we like better than 10x Genomics
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
